Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma

NCT00478777 is registered in ClinicalTrials.gov with Celgene Corporation as lead sponsor.

NCT NCT00478777
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00478777 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma
Lead sponsor
Celgene Corporation
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2007
Completion date
August 31, 2009
Enrollment
150 (actual)
Sites
48

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed or refractory multiple myeloma